Follow
Martin Marquis
Martin Marquis
Unknown affiliation
Verified email at ssss.gouv.qc.ca
Title
Cited by
Cited by
Year
Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase
G Kukolj, GA McGibbon, G McKercher, M Marquis, S Lefebvre, ...
Journal of Biological Chemistry 280 (47), 39260-39267, 2005
1642005
Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells
PL Beaulieu, Y Bousquet, J Gauthier, J Gillard, M Marquis, G McKercher, ...
Journal of medicinal chemistry 47 (27), 6884-6892, 2004
1232004
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA
A Pause, G Kukolj, M Bailey, M Brault, F Dô, T Halmos, L Lagacé, ...
Journal of Biological Chemistry 278 (22), 20374-20380, 2003
1212003
A disulfide-bridged mutant of natriuretic peptide receptor-A displays constitutive activity: role of receptor dimerization in signal transduction
J Labrecque, N Mc Nicoll, M Marquis, A De Léan
Journal of Biological Chemistry 274 (14), 9752-9759, 1999
861999
Risk of delayed intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: systematic review and meta-analysis
JM Chauny, M Marquis, F Bernard, D Williamson, M Albert, M Laroche, ...
The Journal of emergency medicine 51 (5), 519-528, 2016
842016
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment
A Erhardt, K Deterding, Y Benhamou, M Reiser, X Forns, S Pol, JL Calleja, ...
Antiviral therapy 14 (1), 23-32, 2009
832009
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin
D Larrey, AW Lohse, V De Ledinghen, C Trepo, T Gerlach, JP Zarski, ...
Journal of hepatology 57 (1), 39-46, 2012
532012
In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335
L Lagacé, PW White, C Bousquet, N Dansereau, F Dô, M Llinas-Brunet, ...
Antimicrobial agents and chemotherapy 56 (1), 569-572, 2012
532012
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir
KL Berger, I Triki, M Cartier, M Marquis, MJ Massariol, WO Böcher, ...
Antimicrobial agents and chemotherapy 58 (2), 698-705, 2014
422014
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency
O Hucke, R Coulombe, P Bonneau, M Bertrand-Laperle, C Brochu, ...
Journal of medicinal chemistry 57 (5), 1932-1943, 2014
362014
Antiviral effect, safety, and pharmacokinetics of five-day oral administration of deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in …
D Larrey, AW Lohse, C Trepo, JP Bronowicki, K Arastéh, M Bourlière, ...
Antimicrobial agents and chemotherapy 57 (10), 4727-4735, 2013
292013
Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3–NS4A proteins
MJ Massariol, S Zhao, M Marquis, D Thibeault, PW White
Biochemical and biophysical research communications 391 (1), 692-697, 2010
282010
Prognostic impact of the conversion to a shockable rhythm from a non-shockable rhythm for patients suffering from out-of-hospital cardiac arrest
A Cournoyer, S Cossette, BJ Potter, R Daoust, L de Montigny, ...
Resuscitation 140, 43-49, 2019
272019
Inhibitor-resistant HCV NS3 protease
G Kukolj, L Lagacé, M Marquis, D Lamarre, A Pause
US Patent 7,208,309, 2007
272007
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study
KL Berger, L Lagacé, I Triki, M Cartier, M Marquis, C Lawetz, R Bethell, ...
Antimicrobial agents and chemotherapy 57 (10), 4928-4936, 2013
232013
Genotypic and Phenotypic Analysis of the NS5B Polymerase Region from Viral Isolates of HCV Chronically Infected Patients Treated with BI 207127 for 5 Days' Monotherapy
L Lagace, M Cartier, G Laflamme, C Lawetz, M Marquis, I Triki, ...
Hepatology 52 (4), 1205A-1206A, 2010
222010
Evaluating acute pain intensity relief: challenges when using an 11-point numerical rating scale
JM Chauny, J Paquet, G Lavigne, M Marquis, R Daoust
Pain 157 (2), 355-360, 2016
202016
Evaluation of interventions to reduce opioid prescribing for patients discharged from the emergency department: a systematic review and meta-analysis
R Daoust, J Paquet, M Marquis, JM Chauny, D Williamson, V Huard, ...
JAMA network open 5 (1), e2143425-e2143425, 2022
162022
Oxygen therapy and risk of infection for health care workers caring for patients with viral severe acute respiratory infection: a systematic review and meta-analysis
A Cournoyer, S Grand’Maison, AM Lonergan, J Lessard, JM Chauny, ...
Annals of Emergency Medicine 77 (1), 19-31, 2021
132021
822 PRECLINICAL CHARACTERIZATION OF THE HEPATITIS C VIRUS NS5B POLYMERASE NON-NUCLEOSIDE INHIBITOR BI 207127
PL Beaulieu, PC Anderson, C Brochu, M Bos, M Cordingley, J Duan, ...
Journal of Hepatology, S321, 2012
132012
The system can't perform the operation now. Try again later.
Articles 1–20